Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$226.4MCash, Jun 2026
17moCash Runway (est.)
+43%Share Count, 1 Year
Follow KYTX by emailGet an email when KYTX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about KYTX, unsubscribe in one click. Privacy
📣 What KYTX Says Is Next
mid-2027 · “The Phase 3 trial is expected to complete enrollment by mid-2027.”
Company press release, Sep 24, 2026 · SEC filing
mid-2027 · “The Phase 3 portion of the KYSA-6 trial is ongoing, with enrollment expected to be completed in mid-2027.”
Company press release, Sep 24, 2026 · SEC filing
Q4 2026 · “Kyverna intends to include the one-year data in its rolling Biologics License Application (BLA) submission, which is on track to be completed in Q4 2026.”
Company press release, Sep 24, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
KYTX reported $226.4M in cash and short-term investments (as of Jun 30, 2026) and used about $41.3M/quarter in operations, an estimated runway of 16.5 months at that rate (BioRadar estimate, not company guidance).
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KYTX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.